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Infections caused by the protozoan parasites Trypanosoma
cruzi, Trypanosoma brucei, and Leishmania spp. are among
the most relevant public health problems in the developing
countries. Furthermore, climatic changes and migratory
fluxes of the human population are broadening the former
geographic restrictions of most of these diseases. Only a few
therapeutic treatments are available for these infections, and
main drawbacks of drugs in use are their low eﬃciency, high
toxicity, and the emergence of strains resistant to available
treatments. All these facts make the research on new drug
targets and strategies for developing new drug therapeutic
strategies a relevant issue.
In this special issue, we presented original research papers
and reviews on the discovery of novel enzyme targets which
contributed to having a picture of the state of the art on
trypanosomatids’ enzymes research oriented to therapeutic
applications. The topics addressed in this special edition
include a wide variety of enzymes and metabolic pathways:
biosynthesis of galactofuranose (M. Oppenheimer et al.),
prereplication machinery (S. G. Calderano et al.), glutamate
metabolism (A. Magdaleno et al.), ornithine decarboxylases
(J. J. Barclay et al.), sphingolipid biosynthetic (C. M. Koeller
and N. Heise), phosphotransferase enzymes involved in cell
energy management (C. A. Pereira et al.), Heme metabolic
pathway (K. E. J. Tripodi et al.), phospholipases A (M. L.
Belaunzaran et al.), topoisomerases (B. Banerjee et al.), P4
Nucleases (L. Rahbarnia et al.), enolases (L. Avilan et al.)
and in silico prediction of drug targets by non-homologous
isofunctional enzymes analysis (M. Rajao Gomes et al.).
I hope the information in this special issue will be useful
not only for scientists in the area, but also as a status report
on this critical issue for developing countries.
Claudio Alejandro Pereira
Ariel Mariano Silber
Elena Gonzalez-Rey
